Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 8 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors at 2 institutions in 1 country.
Melanie J PredebonPancreatic Cancer Research Group, School of Environmental and Life Sciences, The University of Newcastle, Ourimbah, NSW 2258, Australia. melanie.predebon@uon.edu.au.
Danielle R BondPancreatic Cancer Research Group, School of Environmental and Life Sciences, The University of Newcastle, Ourimbah, NSW 2258, Australia. danielle.bond@newcastle.edu.au.
Joshua BrzozowskiSchool of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, NSW 2308, Australia. joshua.brzozowski@uon.edu.au.ORCID 0000-0001-5508-5257
Helen JankowskiSchool of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, NSW 2308, Australia. helen.jankowski@uon.edu.au.
Fiona DeaneChemistry, School of Environmental and Life Sciences, The University of Newcastle, Callaghan, NSW 2308, Australia. fiona.deane@newcastle.edu.au.
Mark TarletonPancreatic Cancer Research Group, School of Environmental and Life Sciences, The University of Newcastle, Ourimbah, NSW 2258, Australia. mark.tarleton@uon.edu.au.
Aron A ShawChemistry, School of Environmental and Life Sciences, The University of Newcastle, Callaghan, NSW 2308, Australia. aron.shaw@uon.edu.au.
Adam McCluskeyChemistry, School of Environmental and Life Sciences, The University of Newcastle, Callaghan, NSW 2308, Australia. adam.mccluskey@newcastle.edu.au.ORCID 0000-0001-7125-863X
Michael C BowyerPancreatic Cancer Research Group, School of Environmental and Life Sciences, The University of Newcastle, Ourimbah, NSW 2258, Australia. michael.bowyer@newcastle.edu.au.
Judith WeidenhoferSchool of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, NSW 2308, Australia. judith.weidenhofer@newcastle.edu.au.ORCID 0000-0003-1218-4903
Christopher J ScarlettPancreatic Cancer Research Group, School of Environmental and Life Sciences, The University of Newcastle, Ourimbah, NSW 2258, Australia. c.scarlett@newcastle.edu.au.ORCID 0000-0002-4140-7785
Hunter Medical Research Institute · AUUniversity of Newcastle Australia · AU
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Pancreatic cancer (PC) is a complex, heterogeneous disease with a dismal prognosis. Current therapies have failed to improve survival outcomes, urging the need for discovery of novel targeted treatments. Bispidinone derivatives have yet to be investigated as cytotoxic agents against PC cells. The cytotoxic effect of four bispidinone derivatives (
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The Bispidinone Derivative 3,7-Bis-[2-( · full record | OpenQuestion